Physician profile
William J Henry
NPI 1518935832
$5,057.08
in general payments reported to CMS, 2019-2025
41 companies · $23.01 in 2025
The $23.01 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,508 · 2020: $701 · 2021: $540 · 2022: $773 · 2023: $1,357 · 2024: $155 · 2025: $23.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.85 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Novartis Pharmaceuticals Corporation | $318.78 | 2019-2023 | |
| Esperion Therapeutics, INC. | $309.52 | 2020-2022 | |
| Abbott Laboratories | $293.40 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $271.99 | 2019-2023 | Spravato |
| Abbvie INC. | $267.85 | 2022-2024 | |
| Amarin Pharma, INC. | $266.03 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $256.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.97 | 2022-2023 | |
| Lilly USA, LLC | $212.02 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $207.79 | 2019-2022 | |
| Amgen INC. | $204.32 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.72 | 2019-2023 | Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $179.88 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $135.93 | 2019-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.